Announcing LightWave II: LM® LLLT for Dry AMD Global Research Study

 

Bologna, Italy — April 28th 2023

Espansione Group, the leading medical device company offering screening and treatment solutions for ocular health, announces today the second wave of its major research effort aimed at contributing to the prevention and management of dry AMD.    

Having announced the European study LightWave I at ESCRS 2022 in Milan, Espansione Group is today announcing a second large-scale, global multi-center clinical trial focused on non-neovascular (dry) Age-Related Macular Degeneration (AMD) through its patented technology Light Modulation® Low-level Light Therapy (LM® LLLT), a medical-grade photobiomodulation (PBM) technology already benefitting with strong support from the scientific community with dozens of papers and articles published to date.  

LightWave II is being announced today with the aim of strengthening the already existing body of research around PBM in AMD management, fill the knowledge gaps of LightWave I, and move beyond Europe with an additional focus on the American and Asia-Pacific Continents.   

Clinical trials conducted to date focusing on PBM in the field of retinal diseases have demonstrated better anatomical and functional outcomes for patients treated with LLLT vs. control groups. A large array of positive clinical findings, coupled with the well-known mitochondrial-based mode of action of LM® LLLT highly suggest that LLLT treatment could have a therapeutic role in dry AMD. 

For practitioners, research centers and universities interested in staying in touch and learning more about LightWave II, its protocol and any future development get in touch on our website.

> ABOUT AMD

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. The dry AMD subtype accounts for 85-90% of cases, with a global prevalence of 0.44%, increasing with age. Over 280 million people will be affected by 2040. With a global prevalence amongst the elderly, dry AMD is a multifactorial disease: age, genetics, race (most common for caucasians), smoking, obesity and cardiovascular diseases are the main factors playing a role in augmenting the risk of dry AMD arising.

SOURCE: SCHULTZ NM, ET AL. "GLOBAL BURDEN OF DRY AGE-RELATED MACULAR DEGENERATION: A TARGETED LITERATURE REVIEW." CLIN THER. 2021;43(10):1792-1818 

> ABOUT ESPANSIONE GROUP

Espansione Group is an established player in the MedTech industry. Since 1981, Espansione Group has delivered the highest standard in the industry. Every day, the company invests heavily in researching and developing the Espansione Ecosystem to achieve its ambition: establishing new paradigms in ophthalmology and beyond, driven by its desire to provide its partners and their patients with the best, certified medical technologies, Light Modulation® Low-level Light Therapy (LM® LLLT) and Optimal Power Energy® Intense Pulsed Light (OPE® IPL). Present in over 50 countries, Espansione Group's aims to continue its strong growth in years to come, relentlessly focusing its efforts on research, development, and customer excellence. 

For more information, see www.espansionegroup.it

MEDIA CONTACTS

Espansione Group 
Press Office
press@espansione.it 

© 2023 Espansione Group, All Rights Reserved 
Posted on April 28th, 2023 in Newsroom